Topiramate for weight reduction in adolescents with severe obesity

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background. Medications for use as an adjunct to lifestyle modification therapy (LSM) for severe adolescent obesity are limited. Topiramate results in weight reduction in adults with obesity, but has not been studied in adolescents.

Objective. To examine the effect of topiramate plus LSM on body mass index (BMI) reduction in adolescents with severe obesity.

Methods. Data for this retrospective chart review were collected from patients attending a pediatric weight management program who were treated with LSM plus topiramate for 3 months minimum. Mean BMI percent change from baseline was evaluated using t-tests.

Results. Twenty-eight patients (mean age 15.2 ± 2.5 years, mean baseline BMI 46.2 ± 10.3 kg/m2) were identified for inclusion. The 6-month percent change in BMI was -4.9, 95% confidence interval (-7.1, -2.8), P <.001.

Conclusions. Topiramate with concurrent LSM was associated with clinically meaningful BMI reduction in adolescents with severe obesity. Randomized controlled clinical trials examining efficacy and safety of topiramate for severe obesity in adolescents are needed.

Original languageEnglish (US)
Pages (from-to)19-24
Number of pages6
JournalClinical Pediatrics
Volume54
Issue number1
DOIs
StatePublished - Jan 10 2015

Fingerprint

Morbid Obesity
Weight Loss
Body Mass Index
Life Style
Pediatric Obesity
Therapeutics
Randomized Controlled Trials
Obesity
topiramate
Confidence Intervals
Pediatrics
Safety
Weights and Measures

Keywords

  • adolescent
  • medication
  • obesity
  • pharmacotherapy
  • topiramate

Cite this

Topiramate for weight reduction in adolescents with severe obesity. / Fox, Claudia K.; Marlatt, Kara L.; Rudser, Kyle D.; Kelly, Aaron S.

In: Clinical Pediatrics, Vol. 54, No. 1, 10.01.2015, p. 19-24.

Research output: Contribution to journalArticle

@article{03da688cf4d14ad3b10fe531cb991f15,
title = "Topiramate for weight reduction in adolescents with severe obesity",
abstract = "Background. Medications for use as an adjunct to lifestyle modification therapy (LSM) for severe adolescent obesity are limited. Topiramate results in weight reduction in adults with obesity, but has not been studied in adolescents.Objective. To examine the effect of topiramate plus LSM on body mass index (BMI) reduction in adolescents with severe obesity.Methods. Data for this retrospective chart review were collected from patients attending a pediatric weight management program who were treated with LSM plus topiramate for 3 months minimum. Mean BMI percent change from baseline was evaluated using t-tests.Results. Twenty-eight patients (mean age 15.2 ± 2.5 years, mean baseline BMI 46.2 ± 10.3 kg/m2) were identified for inclusion. The 6-month percent change in BMI was -4.9, 95{\%} confidence interval (-7.1, -2.8), P <.001.Conclusions. Topiramate with concurrent LSM was associated with clinically meaningful BMI reduction in adolescents with severe obesity. Randomized controlled clinical trials examining efficacy and safety of topiramate for severe obesity in adolescents are needed.",
keywords = "adolescent, medication, obesity, pharmacotherapy, topiramate",
author = "Fox, {Claudia K.} and Marlatt, {Kara L.} and Rudser, {Kyle D.} and Kelly, {Aaron S.}",
year = "2015",
month = "1",
day = "10",
doi = "10.1177/0009922814542481",
language = "English (US)",
volume = "54",
pages = "19--24",
journal = "Clinical Pediatrics",
issn = "0009-9228",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Topiramate for weight reduction in adolescents with severe obesity

AU - Fox, Claudia K.

AU - Marlatt, Kara L.

AU - Rudser, Kyle D.

AU - Kelly, Aaron S.

PY - 2015/1/10

Y1 - 2015/1/10

N2 - Background. Medications for use as an adjunct to lifestyle modification therapy (LSM) for severe adolescent obesity are limited. Topiramate results in weight reduction in adults with obesity, but has not been studied in adolescents.Objective. To examine the effect of topiramate plus LSM on body mass index (BMI) reduction in adolescents with severe obesity.Methods. Data for this retrospective chart review were collected from patients attending a pediatric weight management program who were treated with LSM plus topiramate for 3 months minimum. Mean BMI percent change from baseline was evaluated using t-tests.Results. Twenty-eight patients (mean age 15.2 ± 2.5 years, mean baseline BMI 46.2 ± 10.3 kg/m2) were identified for inclusion. The 6-month percent change in BMI was -4.9, 95% confidence interval (-7.1, -2.8), P <.001.Conclusions. Topiramate with concurrent LSM was associated with clinically meaningful BMI reduction in adolescents with severe obesity. Randomized controlled clinical trials examining efficacy and safety of topiramate for severe obesity in adolescents are needed.

AB - Background. Medications for use as an adjunct to lifestyle modification therapy (LSM) for severe adolescent obesity are limited. Topiramate results in weight reduction in adults with obesity, but has not been studied in adolescents.Objective. To examine the effect of topiramate plus LSM on body mass index (BMI) reduction in adolescents with severe obesity.Methods. Data for this retrospective chart review were collected from patients attending a pediatric weight management program who were treated with LSM plus topiramate for 3 months minimum. Mean BMI percent change from baseline was evaluated using t-tests.Results. Twenty-eight patients (mean age 15.2 ± 2.5 years, mean baseline BMI 46.2 ± 10.3 kg/m2) were identified for inclusion. The 6-month percent change in BMI was -4.9, 95% confidence interval (-7.1, -2.8), P <.001.Conclusions. Topiramate with concurrent LSM was associated with clinically meaningful BMI reduction in adolescents with severe obesity. Randomized controlled clinical trials examining efficacy and safety of topiramate for severe obesity in adolescents are needed.

KW - adolescent

KW - medication

KW - obesity

KW - pharmacotherapy

KW - topiramate

UR - http://www.scopus.com/inward/record.url?scp=84916214018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916214018&partnerID=8YFLogxK

U2 - 10.1177/0009922814542481

DO - 10.1177/0009922814542481

M3 - Article

C2 - 25027265

AN - SCOPUS:84916214018

VL - 54

SP - 19

EP - 24

JO - Clinical Pediatrics

JF - Clinical Pediatrics

SN - 0009-9228

IS - 1

ER -